Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Healthcare Reform Proposals Expected No Sooner Than Fall
February 26, 2001
- Welfide Licenses Agent for Diabetic Neuropathy to Takeda
February 26, 2001
- Additional Indications Required to Commercialize Artificial Erythrocytes
February 26, 2001
- Fujisawa Launches Protopic in US
February 26, 2001
- Aventis Behring Launches Web Site
February 26, 2001
- Worldwide Sales of Yakult's Irinotecan to Top \150 Bil. in 2005
February 26, 2001
- Council Starts Discussions to Improve Drug Information Supply System
February 26, 2001
- Kyorin, Ono to Codevelop Drug for Urinary Incontinence
February 26, 2001
- METI Report Calls For Free Competition for Medical, Nursing Care Services
February 26, 2001
- BUSINESS NEWS IN BRIEF -1-
February 26, 2001
- Elimination of NHI Price SystemShould Be Considered: Prof. Tokita
February 26, 2001
- REGULATORY NEWS IN BRIEF
February 26, 2001
- WORLD BUSINESS NEWS IN BRIEF
February 26, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 26, 2001
- New Law Specific for Medical Devices Is Necessary: JFITMA President
February 26, 2001
- Kirin to Sponsor Genomic Medical Engineering Course at Tottori Univ.
February 26, 2001
- New ARIA Guidelines Prepared by WHO for Allergic Rhinitis
February 26, 2001
- Delisting Should Be Considered for Certain Drugs: Finance Ministry Officer
February 19, 2001
- Nihon Nosan Kogyo Forms Alliance with PPL Therapeutics of UK for Genomic Technology
February 19, 2001
- Japan, EU Mutual GMP Recognition Coming Soon
February 19, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…